Cite
MLA Citation
Steven Horwitz et al.. “Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.” Lancet, vol. 393, no. 10168, 2019, pp. 229–240. http://access.bl.uk/ark:/81055/vdc_100076796556.0x000049